11:18 AM EDT, 03/20/2024 (MT Newswires) -- Puma Biotechnology ( PBYI ) said Wednesday that it intends to begin a phase 2 breast cancer study that will evaluate alisertib in combination with endocrine treatment in the second half of 2024.

The company said it was notified by the US Food and Drug Administration that its investigational new drug application submission for alisertib has been reviewed.

Puma Biotechnology ( PBYI ) said it can proceed with the phase 2 study of alisertib to treat patients who have human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer in the study.

The company's shares were up 6.5% in recent trading.

Price: 4.58, Change: +0.28, Percent Change: +6.51